Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals (ARWR)
NASDAQ:ARWR
RESEARCH TOOLSreports
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.11Last Year’s EPS
-1.02Same Quarter Last Year
Moderate Buy
Based on 11 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 10, 2025
|% Change Since: 5.22%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with major highlights such as the closing of a significant deal with Sarepta Therapeutics, upcoming launches, and strong pipeline advancements in obesity and CNS. However, increased operating expenses and a higher net loss were noted as lowlights, with some uncertainties regarding the timing of the CVOT for plozasiran.Company Guidance
In the recent earnings call, Arrowhead Pharmaceuticals provided guidance highlighting several key financial metrics and strategic initiatives. The company announced the closure of its license and collaboration agreement with Sarepta Therapeutics, which includes a $500 million upfront payment and $325 million from Sarepta's purchase of Arrowhead common stock at $27.25 per share. Arrowhead is also set to receive $250 million over five years in annual installments of $50 million and has the potential for an additional $300 million in near-term payments related to a Phase I/II study of ARO-DM1. Additionally, the deal includes potential development milestone payments ranging from $110 million to $410 million per program and sales milestone payments between $500 million and $700 million per program, with the total potential value exceeding $11 billion. The company is now funded into 2028, with strategic focus areas including plozasiran, obesity, and CNS, as well as plans for a Phase III study for zodasiran. Arrowhead expects its first commercial launch of plozasiran, pending FDA approval, by the end of the year and anticipates the product could become a $2 billion to $3 billion yearly revenue generator in the SHTG market alone.Sarepta Therapeutics Collaboration
Arrowhead closed a significant collaboration agreement with Sarepta Therapeutics, expecting to receive $500 million upfront and a total potential value exceeding $11 billion, providing substantial capital infusion and reducing R&D expenses.
Plozasiran Commercial Launch
Pending FDA approval, Arrowhead anticipates the commercial launch of plozasiran for FCS by late 2025, with potential to become a $2 billion to $3 billion per year drug in the SHTG market alone.
Obesity Program Advances
Initiation of Phase I/II clinical trials for obesity candidates ARO-INHBE and ARO-ALK7, with promising preclinical results in fat mass reduction and muscle mass preservation.
CNS Pipeline Development
Development of CNS pipeline with potential treatments for Huntington's, Alzheimer's, and Parkinson's diseases, leveraging new TRiM platform capable of delivering sRNA across the blood-brain barrier.
Strong Cash Position
Arrowhead reports a pro forma cash balance of $1.4 billion, providing runway into 2028 and supporting future growth initiatives.
---
ARWR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ARWR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 10, 2025 | $19.92 | $18.89 | -5.17% |
| Nov 26, 2024 | $21.05 | $26.15 | +24.23% |
| Aug 08, 2024 | $25.85 | $23.41 | -9.44% |
| May 09, 2024 | $24.72 | $22.08 | -10.68% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Arrowhead Pharmaceuticals (ARWR) report earnings?
Arrowhead Pharmaceuticals (ARWR) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is Arrowhead Pharmaceuticals (ARWR) earnings time?
Arrowhead Pharmaceuticals (ARWR) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ARWR EPS forecast?
ARWR EPS forecast for the fiscal quarter 2025 (Q2) is -0.11.
---